AbCellera Biologics Inc.

ABCLNASDAQHealthcare● Active

$5.42

$-0.20(-3.56%)

Market Cap$1.7B

P/E Ratio—

52W High$6.79

52W Low$2.33

Avg Volume5.9M

Open$5.86

Beta1.18

Cash on Hand Financials Revenue

AbCellera Biologics Inc. (ABCL) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

ABCL · cash on hand · updated Dec 31, 2025

Core cash position

as of Dec 31, 2025

Cash & Short-Term Investments (CCE + ST Investments)

$533.8M▼ -14.7% vs prior year

FY · as of Dec 31, 2025 · Reported in USD

Cash & Cash Equiv. (CCE)

$128.5M

cashAndCashEquivalents

Short-Term Investments

$405.3M

shortTermInvestments

YoY Change vs Prior Year

-14.7%

vs prior fiscal year

Latest Quarter

$504.7M

Q1 2026

Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash vs Debt · Balance Sheet Health

Cash & ST Investments$533.8MCash on Hand

Total Debt$143.2MTotal Debt

Net Cash / Net Debt+$390.6MNet Cash Position

Cash vs Debt Ratio

Cash 79%AbCellera Biologics Inc. cash as % of market cap: 32.25%% · MCap $2BDebt 21%

AbCellera Biologics Inc. has a net cash position of $390.6M, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$533.8M − $143.2M = +$390.6M

Cash on hand history

annual cash on hand trend · Cash & Short-Term Investments

YoY Increase

YoY Decrease

Latest Year

ABCL annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

ABCL cash & short-term investments history

DatePeriodCash & ST InvestmentsYoY Change

Dec 31, 2025LatestFY$533.8M-14.7%

Dec 31, 2024FY$625.6M-17.7%

Dec 31, 2023FY$760.6M-14.2%

Dec 31, 2022FY$886.5M+22.6%

Dec 31, 2021FY$723.0M+21.7%

ABCL cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

ABCL vs peers · cash on hand

#CompanyCash & ST Inv.Market CapCash/MCapRelative

UnitedHealth Group Incorporated

Eli Lilly and Company

AbCellera Biologics Inc.YOU

ABCL

$533.8M$2B32.3%

Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

AbCellera Biologics Inc. (ABCL) cash on hand as of December 31, 2025 is $533.8M, comprising $128.5M in cash and cash equivalents (CCE) plus $405.3M in short-term investments — reported as AbCellera Biologics Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as AbCellera Biologics Inc. cash reserves or cash position.

AbCellera Biologics Inc. annual cash on hand history shows decreased -14.7% in 2025: decreased -14.7% in 2025. AbCellera Biologics Inc. cash reserves in 2025 reflect the company's capital allocation strategy.

AbCellera Biologics Inc. carries total debt of $143.2M against cash of $533.8M, resulting in a net cash position of +$390.6M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.

Financial statements Free cash flow Net income Revenue Market cap P/E ratio Earnings Price history

Frequently asked questions

ABCL cash on hand · 5 questions

As of December 31, 2025, AbCellera Biologics Inc. (ABCL) has $533,826,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $128,513,000 in cash and cash equivalents (CCE) plus $405,313,000 in short-term investments. Latest quarter (March 31, 2026): $504,732,000. Data sourced from the annual 10-K filing via FMP.

ABCL cash on handABCL cash reservesABCL cash 2025how much cash does ABCL have

▸ Source: FMP /balance-sheet-statement · US GAAP · AbCellera Biologics Inc. · AbCellera Biologics Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025